Biblio
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12(12):165.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med. 2023;388(19):1739-1754.
High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse. Med Oncol. 2013;30(4):762.
. Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry. Eur J Haematol. 2019.
Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: the case of subset #2. Epigenetics. 2016.
. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Adv. 2020;4(6):1094-1101.
Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. Blood. 2023.
Secondary acute myeloid leukemia and the role of allogeneic stem cell transplantation in a population-based setting. Biol Blood Marrow Transplant. 2019.
Subpopulations of T regulatory cells in blood stem cell harvests influence development of acute graft vs. host disease in allogeneic transplant recipients. Cytometry B Clin Cytom. 2016.
. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?. Haematologica. 2015.
. Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia. Lancet Haematol. 2022;9(5):e317-e318.
.